Dr. McLaughlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
148 Chestnut St
Needham, MA 02492Phone+1 781-453-5238Fax+1 781-453-5260
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Clinical Cardiac Electrophysiology, 2003 - 2004
- Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 2000 - 2003
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1997 - 2000
- Johns Hopkins University School of MedicineClass of 1997
Certifications & Licensure
- MA State Medical License 1999 - 2026
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Clinical Cardiac Electrophysiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Publications & Presentations
PubMed
- 5 citationsJOURNAL CLUB: Voice Recognition Dictation: Analysis of Report Volume and Use of the Send-to-Editor FunctionDennis R. Williams, Sheila K. Kori, Brenda Williams, Sandra J. Sackrison, Henryk M. Kowalski
AJR. American Journal of Roentgenology. 2013-10-22 - 95 citationsPaced left ventricular QRS width and ECG parameters predict outcomes after cardiac resynchronization therapy: PROSPECT-ECG substudy.Jeff Hsing, Kimberly A. Selzman, Christophe Leclercq, Luis A. Pires, Michael G. McLaughlin
Circulation. Arrhythmia and Electrophysiology. 2011-12-01 - 71 citationsImpact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Int...Paul Sorajja, Bernard J. Gersh, David A. Cox, Michael G. McLaughlin, Peter Zimetbaum
Journal of the American College of Cardiology. 2010-04-06
Press Mentions
- Dermavant Announces Presentation of Tapinarof Pivotal Phase 3 PSOARING Data at Fall Clinical Dermatology ConferenceOctober 22nd, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: